Covid19 Clinical Trial
— SACSOSOfficial title:
The South African COVID-19 Surgical Outcomes Study - A Prospective Observational Cohort Study of Long-term Patient-reported Outcomes After Surgery Using a Digital Health Platform
The infectious coronavirus disease of 2019 (COVID-19), caused by corona virus SARS-severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) has caused significant disruption in surgical services to patients globally. Data from the COVIDSurg Cohort Study suggest mortality rates of patients infected with SARS-Cov-2 in the peri-operative period of up to 25.6% in emergency surgery and 18.9% in elective surgery. Based on estimates by the COVIDSurg Collaborative, large numbers of elective surgical procedures are cancelled. The COVID-19 pandemic has forced healthcare providers to 'shift from patient-centred ethics to public health ethics'. This has had impact on pre-operative testing for COVID-19, and scheduling of surgery. Currently, a provisional recommendation to delay surgery for at least four weeks after a positive COVID test, exists. Weighing the risk of surgery and potential complications during the COVID-19 pandemic, against the benefit of undergoing a surgical procedure to improve quality of life, remains difficult. A study to determine the long term effect of the pandemic on patient-reported outcome may provide guidance on how to safely return to surgical activity that are again more focused on individualized care. There is also the opportunity to record outcomes that are currently accepted as the standard for understanding longer term recovery after surgery.
Status | Not yet recruiting |
Enrollment | 1000 |
Est. completion date | December 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients presenting for any surgical procedure at South African hospitals during the specified study period. Exclusion Criteria: - Patients unable to provide consent to participation. - Patients whose legal guardian is unable to provide consent to participation (if applicable). - Patients unable to nominate next-of-kin, guardian of or a person of their choice, as their representative during follow-up. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sefako Makgatho Health Sciences University | Medical Research Council, South Africa, University of Cape Town |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of Life using EQ-5D-5L (terminology for the descriptive system) score | The questionnaire provides a simple descriptive profile of a respondent's health state. | 6 Months post-operatively | |
Primary | Quality of Life using EQ-5D-5L (terminology for the descriptive system) score | The questionnaire provides a simple descriptive profile of a respondent's health state. | 12 Months post-operatively | |
Secondary | In-Hospital Mortality | Mortality while admitted to hospital | 30 days postoperatively | |
Secondary | 30 Day Mortality | Mortality at 30 Days | 30 days | |
Secondary | In-Hospital Post-Operative Morbidity | Using the Peri-Operative Morbidity Survey (POMS) | 30 days | |
Secondary | 30 Day Post-Operative Morbidity | Using the Peri-Operative Morbidity Survey (POMS) | 30 days post-operatively | |
Secondary | Post-Operative Intensive Care Unit Length of Stay | Admission to Intensive Care for any reason post-operatively. Distinguishing between planned and unexpected ICU admissions. | 30 days postoperatively | |
Secondary | Post-Operative Hospital Length of Stay | Total duration of admission, including days admitted to Intensive Care Unit or High Care Unit and days admitted to ward. | 30 days postoperatively | |
Secondary | Quality of Recovery | Using the Quality of Recovery 15 (QoR15) Scale. | 24-48 hours Post-Operatively | |
Secondary | Covid19 Diagnosis | Any patient reported diagnosis of Covid19. | 30 days post-operatively | |
Secondary | Post-Operative Complications | Post-Operative complications reported by patient or physician. | 30 days post-operatively | |
Secondary | Readmission to Hospital | Readmission for any reason | 30 days post-operatively | |
Secondary | Days Alive and Out of Hospital (DAOH) | Standardised patient-centered outcome measure, evaluating number of days alive and out of hospital. | 30 days post-operatively | |
Secondary | Functional status | Using the WHO Disability Assessment Score (WHODAS) | 6 months post-operatively | |
Secondary | Functional status | Using the WHO Disability Assessment Score (WHODAS) | 12 months post-operatively | |
Secondary | Hospital Cost | As reported by hospital manager | 30 days postoperatively |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |